Bisphosphonate use and risk of renal cell carcinoma

a population-based case-control study

Benjamin I Chung, Maja Hellfritzsch, Sinna Pilgaard Ulrichsen, Henrik Toft Sørensen, Vera Ehrenstein

Publikation: Bidrag til tidsskriftLetterForskningpeer review

Resumé

The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell carcinoma (RCC). We conducted a case-control study in Denmark, using data linked from population-based health and administrative registries. We identified all cases of RCC from 1996 to 2013 and sampled population controls in a 10:1 ratio from the underlying population free of RCC, while matching on sex, birth year and calendar time. Bisphosphonate use before RCC diagnosis, excluding the year leading up to the diagnosis, was measured using outpatient prescription dispensations. We used conditional logistic regression to compute crude and adjusted odds ratios (ORs) comparing ever vs. never bisphosphonate use in doses indicated for treatment of osteoporosis, overall and stratified by sex, with the OR estimating the incidence rate ratio. We also examined the effects by cumulative dose and specific agent. There were 2748 RCC cases and 27,480 controls. The adjusted ORs for ever vs. never bisphosphonate use were 1.07 (95% confidence interval: 0.94-1.22) overall; 1.15 (1.00-1.32) for women; and 0.78 (0.54-1.12) for men. Smoking could not be directly controlled for in the analysis. We found a weak association between use of oral bisphosphonates and risk of renal cell carcinoma in females. The observed association could be due to confounding by cigarette smoking, and future studies are required to assess this association further. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftBasic & Clinical Pharmacology & Toxicology
Vol/bind124
Udgave nummer5
Sider (fra-til)642-646
ISSN1742-7835
DOI
StatusUdgivet - 1. maj 2019

Fingeraftryk

Diphosphonates
Case-Control Studies
Cells
Population
Odds Ratio
Smoking
Population Control
Tobacco Products
Denmark
Logistics
Prescriptions
Registries
Health
Outpatients
Logistic Models
Confidence Intervals
Incidence

Citer dette

Chung, Benjamin I ; Hellfritzsch, Maja ; Ulrichsen, Sinna Pilgaard ; Sørensen, Henrik Toft ; Ehrenstein, Vera. / Bisphosphonate use and risk of renal cell carcinoma : a population-based case-control study. I: Basic & Clinical Pharmacology & Toxicology. 2019 ; Bind 124, Nr. 5. s. 642-646.
@article{1049e0ce45aa440ebcacb90d8edddc5a,
title = "Bisphosphonate use and risk of renal cell carcinoma: a population-based case-control study",
abstract = "The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell carcinoma (RCC). We conducted a case-control study in Denmark, using data linked from population-based health and administrative registries. We identified all cases of RCC from 1996 to 2013 and sampled population controls in a 10:1 ratio from the underlying population free of RCC, while matching on sex, birth year and calendar time. Bisphosphonate use before RCC diagnosis, excluding the year leading up to the diagnosis, was measured using outpatient prescription dispensations. We used conditional logistic regression to compute crude and adjusted odds ratios (ORs) comparing ever vs. never bisphosphonate use in doses indicated for treatment of osteoporosis, overall and stratified by sex, with the OR estimating the incidence rate ratio. We also examined the effects by cumulative dose and specific agent. There were 2748 RCC cases and 27,480 controls. The adjusted ORs for ever vs. never bisphosphonate use were 1.07 (95{\%} confidence interval: 0.94-1.22) overall; 1.15 (1.00-1.32) for women; and 0.78 (0.54-1.12) for men. Smoking could not be directly controlled for in the analysis. We found a weak association between use of oral bisphosphonates and risk of renal cell carcinoma in females. The observed association could be due to confounding by cigarette smoking, and future studies are required to assess this association further. This article is protected by copyright. All rights reserved.",
keywords = "bisphosphonates, cigarette smoking, epidemiology, osteoporosis, renal cell carcinoma",
author = "Chung, {Benjamin I} and Maja Hellfritzsch and Ulrichsen, {Sinna Pilgaard} and S{\o}rensen, {Henrik Toft} and Vera Ehrenstein",
note = "This article is protected by copyright. All rights reserved.",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/bcpt.13180",
language = "English",
volume = "124",
pages = "642--646",
journal = "Basic & Clinical Pharmacology & Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell",
number = "5",

}

Bisphosphonate use and risk of renal cell carcinoma : a population-based case-control study. / Chung, Benjamin I; Hellfritzsch, Maja; Ulrichsen, Sinna Pilgaard; Sørensen, Henrik Toft; Ehrenstein, Vera.

I: Basic & Clinical Pharmacology & Toxicology, Bind 124, Nr. 5, 01.05.2019, s. 642-646.

Publikation: Bidrag til tidsskriftLetterForskningpeer review

TY - JOUR

T1 - Bisphosphonate use and risk of renal cell carcinoma

T2 - a population-based case-control study

AU - Chung, Benjamin I

AU - Hellfritzsch, Maja

AU - Ulrichsen, Sinna Pilgaard

AU - Sørensen, Henrik Toft

AU - Ehrenstein, Vera

N1 - This article is protected by copyright. All rights reserved.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell carcinoma (RCC). We conducted a case-control study in Denmark, using data linked from population-based health and administrative registries. We identified all cases of RCC from 1996 to 2013 and sampled population controls in a 10:1 ratio from the underlying population free of RCC, while matching on sex, birth year and calendar time. Bisphosphonate use before RCC diagnosis, excluding the year leading up to the diagnosis, was measured using outpatient prescription dispensations. We used conditional logistic regression to compute crude and adjusted odds ratios (ORs) comparing ever vs. never bisphosphonate use in doses indicated for treatment of osteoporosis, overall and stratified by sex, with the OR estimating the incidence rate ratio. We also examined the effects by cumulative dose and specific agent. There were 2748 RCC cases and 27,480 controls. The adjusted ORs for ever vs. never bisphosphonate use were 1.07 (95% confidence interval: 0.94-1.22) overall; 1.15 (1.00-1.32) for women; and 0.78 (0.54-1.12) for men. Smoking could not be directly controlled for in the analysis. We found a weak association between use of oral bisphosphonates and risk of renal cell carcinoma in females. The observed association could be due to confounding by cigarette smoking, and future studies are required to assess this association further. This article is protected by copyright. All rights reserved.

AB - The purpose of this study was to evaluate the association between the use of bisphosphonates and the risk of developing renal cell carcinoma (RCC). We conducted a case-control study in Denmark, using data linked from population-based health and administrative registries. We identified all cases of RCC from 1996 to 2013 and sampled population controls in a 10:1 ratio from the underlying population free of RCC, while matching on sex, birth year and calendar time. Bisphosphonate use before RCC diagnosis, excluding the year leading up to the diagnosis, was measured using outpatient prescription dispensations. We used conditional logistic regression to compute crude and adjusted odds ratios (ORs) comparing ever vs. never bisphosphonate use in doses indicated for treatment of osteoporosis, overall and stratified by sex, with the OR estimating the incidence rate ratio. We also examined the effects by cumulative dose and specific agent. There were 2748 RCC cases and 27,480 controls. The adjusted ORs for ever vs. never bisphosphonate use were 1.07 (95% confidence interval: 0.94-1.22) overall; 1.15 (1.00-1.32) for women; and 0.78 (0.54-1.12) for men. Smoking could not be directly controlled for in the analysis. We found a weak association between use of oral bisphosphonates and risk of renal cell carcinoma in females. The observed association could be due to confounding by cigarette smoking, and future studies are required to assess this association further. This article is protected by copyright. All rights reserved.

KW - bisphosphonates

KW - cigarette smoking

KW - epidemiology

KW - osteoporosis

KW - renal cell carcinoma

U2 - 10.1111/bcpt.13180

DO - 10.1111/bcpt.13180

M3 - Letter

VL - 124

SP - 642

EP - 646

JO - Basic & Clinical Pharmacology & Toxicology

JF - Basic & Clinical Pharmacology & Toxicology

SN - 1742-7835

IS - 5

ER -